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Understanding the mechanisms of multidrug resistance (MDR) could improve clinical drug efficacy. Multidrug resistance is associated
with ATP binding cassette (ABC) transporters, but the factors that regulate their expression at clinically relevant drug concentrations
are poorly understood. We report that a single-step selection with low doses of anti-cancer agents, similar to concentrations
reported in vivo, induces MDR that is mediated exclusively by ABCG2. We selected breast, ovarian and colon cancer cells (MCF-7,
IGROV-1 and S-1) after exposure to 14 or 21nM doxorubicin for only 10 days. We found that these cells overexpress ABCG2 at the
mRNA and protein levels. RNA interference analysis confirmed that ABCG2 confers drug resistance. Furthermore, ABCG2
upregulation was facilitated by histone hyperacetylation due to weaker histone deacetylase 1-promoter association, indicating that
these epigenetic changes elicit changes in ABCG2 gene expression. These studies indicate that the MDR phenotype arises following
low-dose, single-step exposure to doxorubicin, and further suggest that ABCG2 may mediate early stages of MDR development. This
is the first report to our knowledge of single-step, low-dose selection leading to overexpression of ABCG2 by epigenetic changes in
multiple cancer cell lines.
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Cancer remains a major health issue and is responsible for one in
four deaths in the United States (Zhou et al, 2001; Jemal et al,
2006). The development of multidrug resistance (MDR) to
chemotherapeutic agents plays a major role in the failure of
cancer therapy. Resistance to therapy can result from decreased
drug uptake, increased DNA repair or drug inactivation (Gottesman
et al, 2002). However, the most common mechanism is the
overexpression of ATP binding cassette (ABC) drug transporters
that protect cells by increasing drug efflux. Several investigators
have reported increased ABC transporter expression following
drug treatment (reviewed in Lage, 2003). However, a debate
surrounds the relevance of multistep and continuous selections
with clinically unattainable concentrations commonly used to
study cancer drug resistance.
ATP binding cassette transporters are a large superfamily of
proteins expressed in normal cells in varying amounts. Some
members of this superfamily function to eliminate endogenous and
xenobiotic metabolites, and over 12 ABC transporters have been
linked to MDR. Importantly, there is a substantial overlap in the list of
substrates for ABCB1, ABCG2 and the various ABCC family members
linked with MDR, in spite of significant differences in the primary
sequences of these transporters (Haimeur et al, 2004). This
phenomenon makes treatment of multidrug-resistant cancer unsuc-
cessful despite the various chemotherapeutic drugs that are available.
Cell-based studies of MDR to date have involved establishing
multidrug-resistant cancer cell lines through continual or multi-
step drug selection and using high drug concentrations. Although
these cell lines provided an important tool for understanding ABC
transporter function, these selection regimens do not mimic in
vivo drug concentrations or dosing frequencies that occur in
cancer patients. In this study, we used short, low-dose drug
selection of cancer cell lines to more closely simulate in vivo drug
concentrations such as those used in the liposomal doxorubicin
formulation, which is commonly used as a single-agent therapy for
metastatic breast cancer patients with greater cardiac risks
(Lorusso et al, 2007) and metastatic ovarian cancer refractory to
paclitaxel- and platinum-based chemotherapy (Thigpen et al,
2005). Liposomal doxorubicin is known to have a slow and
sustained release of drug from the liposomal carrier with a half-life
of 55h (Allen et al, 2006). Our in vitro studies utilised doses
significantly below the IC50 of doxorubicin for MCF-7 cells;
concentrations were kept constant over a 10-day period to mimic
the release characteristics from a liposomal carrier. In contrast to
multistep exposure to doxorubicin, where either ABCB1 or ABCC1
is the dominant ABC transporter causing MDR (Shen et al, 1986;
Barrand et al, 1994; Mehta, 1994), we show here that following
single-step selection other transporters, including ABCC4 and
ABCG2, are overexpressed. Importantly, ABCG2 was found to
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sconfer resistance to doxorubicin in breast, ovarian and colon
cancer cell lines. Sequencing of ABCG2 in the single-step-selected
MCF-7 sublines revealed that our in vitro selection resulted in
overexpression of the wild-type ABCG2 and not the gain-of-
function mutations either G or T at amino acid 482. While other
investigators have reported higher resistance to anthracycline with
the 482 mutants (Honjo et al, 2001), we also report increased
resistance to doxorubicin in the sublines with wild-type ABCG2
compared to the parental MCF-7 cells in our studies. Over-
expression of ABCG2 was also observed following single-step low-
dose selection with etoposide. This study shows that ABCG2 may
play a critical role in the development of drug resistance.
MATERIALS AND METHODS
Cell culture
The MCF-7 breast cancer cell line and the multistep doxorubicin-
selected subline MCF7/ADR were a gift of Dr Kapil Mehta
(MD Anderson Cancer Center, Houston, TX, USA) (Mehta,
1994). The multistep doxorubicin-selected MCF-7 cells were
cultured in high-dose doxorubicin (860nM) every alternate passage
as previously described (Mehta, 1994). The generation of MCF-7/
ADR-VP3000 and MCF7/FLV1000 cell lines by multistep selection
was described previously (Chen et al, 1990; Robey et al, 2001).
Spectral karyotyping of these cells matched those described by
others (Kytola et al, 2000). Parental HEK293 cells (293 human
embryonic kidney cells) and the MRP4-overexpressing HEK293/
4.63 cells were gifts of P Borst (The Netherlands Cancer Institute,
Amsterdam, The Netherlands) (Wielinga et al, 2002). HEK293/4.63
cells were reported to express significantly more MRP4 (Reid et al,
2003) without overexpression of other ABC drug transporters and
were cultured as previously described (Wu et al, 2005). The
ovarian IGROV-1 cells were obtained from the Developmental
Therapeutics Program, NCI. S-1 cells, cloned from LS174T colon
carcinoma cells, were described previously (Rabindran et al, 1998).
Drug selection protocol
Drug-resistant MCF-7, IGROV-1 and S-1 clones were established,
employing a single-step selection with either 14 or 21nM
doxorubicin or 300nM etoposide treatment for 10 days followed
by culturing in drug-free medium. Briefly, 10000 cells were seeded
in a 100 20mm tissue culture dish with drug. Medium with drug
was changed three times during the selection and, subsequently,
the cells were maintained in medium without drug. Individual cells
were selected randomly using sterile cloning disks pretreated in
trypsin and placed in separate wells within a 24-well plate. Clones
were grown to confluency and expanded in drug-free media.
Expanded clones were retested for drug resistance before any
further studies. Detailed characterisation of all clones began
approximately 8–12 weeks after single-step selection. The resistant
phenotype in isolated clones was examined 24 weeks after initial
treatment and was found to be stable.
RNA isolation and quantitative RT–PCR
RNA was isolated from cells grown in six-well plates to
characterise ABC transporter expression in all cell lines as
described previously (Wu et al, 2005). Real-time quantitative
RT–PCR (qRT–PCR) was performed using the LightCycler RNA
Master SYBR Green kit and the LightCycler 480 (Roche
Biochemicals, Indianapolis, IN, USA). Plasma membrane calcium
ATPase 4 (PMCA4) was used as the reference gene (Calcagno et al,
2006). Specific PCR conditions and primer sequences for genes are
described in Supplementary Information.
Western blotting
For western blotting assays, equivalent numbers of cells were
harvested and lysed as described previously (Wu et al, 2005).
Nitrocellulose membranes were probed with the appropriate
primary antibodies specific to the protein of interest. The following
antibodies were used: C219 (1:2000), ABCB1 (Kartner et al, 1985);
M2 III-6 (1:50) (Alexis Biochemical, Lausen, Switzerland), ABCC2
(Paulusma et al, 1996); anti-BCRP (1:1000) (Kamiya Biochemical,
Seattle, WA, USA), ABCG2 (Maliepaard et al, 2001); and M4 1-80
(1:200) (Kamiya Biochemical), ABCC4 (Leggas et al, 2004).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1mgml
 1)
(Zymed Laboratories, San Francisco, CA, USA) was used as a
loading control.
Confocal imaging
MCF-7 parental cells and 21nM single-step-selected cells were
seeded at 10000 cells per well on Lab-Tek chamber slides with
covers (Nunc, Rochester, NY, USA). After 48h, the chambers were
washed twice with PBS (Gibco-Invitrogen, Carlsbad, CA, USA),
fixed (IntraPrep kit, Beckman Coulter, Fullerton, CA, USA) for
15min at room temperature (RT), washed three times with wash
buffer (PBS/0.1% bovine serum albumin) and blocked for 1h at RT
with wash buffer. Following two washes with PBS, a 1:100 solution
of the 5D3 clone of the mouse anti-human ABCG2 antibody
(eBioscience, San Diego, CA, USA) in wash buffer was added to all
cell chambers for 1h at RT followed by three washes with wash
buffer. The anti-mouse Alexa Fluor 488-conjugated antibody
(Invitrogen, Carlsbad, CA, USA) (diluted 1:250 in wash buffer)
was incubated with the cells for 30min at RT. Following two
washes with wash buffer, the chambers and seal were removed.
Slides were air dried and mounted in aqueous mounting media
with 40,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories
Inc., Burlingame, CA, USA). Images were acquired using an LSM
510 confocal system mounted on a Zeiss Axiovert 100M
microscope with an oil immersion Plan-Apochromat  63/1.4
NA DIC objective lens (Carl Zeiss, Thornwood, NY, USA).
Excitation of Alexa Fluor 488 was performed using the 488nm
line from a 25mW argon laser while excitation of DAPI was
performed by using the 364nm line from an 80mW UV laser. The
Alexa Fluor 488 emission was collected using a long-pass 505nm
filter and the DAPI emission was collected using a band pass 390–
465nm filter.
Cytotoxicity assay
Sensitivities of cell lines to various chemicals were examined using
the Cell-Counting Kit (CCK) technique as detailed previously
(Ishiyama et al, 1996). Cells were plated at a density of 1000–5000
cells per well in 96-well plates containing 100ml of culture medium.
After 24h incubation at 371C, drugs were added into wells to a final
volume of 200ml per well and incubated for an additional 72h.
CCK reagent was then added into each well and incubated for 4h
before reading at a wavelength of 450nm. IC50 values were
calculated from dose–response curves obtained from at least three
independent experiments.
siRNA design and silencing of ABCG2 expression
The siRNAs employed were designed and synthesised by Qiagen
Inc. (Germantown, MD, USA). The ABCG2-2 siRNA duplex (siG2-2)
consisted of 50-GGAUAAGCCACUCAUAGAAdtdT (sense) and
50-UUCUAUGAGUGGCUUAUCCdTdG (antisense) strands. The
negative siRNA duplex (siNeg) consisted of 50-ACGUGACACGU
UCGGAGAAdTdT and 50-UUCUCCGAACGUGUCACGUdTdT
strands. For siRNA transfections, siRNA (1.25 or 5pmol) was
added to individual wells of a 96-well plate in 25ml serum-free
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sDMEM. Oligofectamine (0.7ml; Invitrogen) was subsequently
added to siRNA-containing wells in 25ml serum-free DMEM to
give a final lipid/siRNA ratio of 2:1 (w/w). The resulting mixture
was allowed to complex for 30min at ambient temperature. Cells
(5000 cells per well – RNA analysis; 1000 cells per well –
cytotoxicity assay) were added in 50ml DMEM supplemented with
20% FBS to yield transfection mixtures of 12.5 or 50nM siRNA in
DMEM containing 10% FBS. This final mixture was incubated at
ambient temperature for 45min before being placed at 371Ci na
humidified atmosphere containing 5% CO2. For initial screening of
siRNA and protein analysis, the transfection protocol was
performed as described above using six-well plates and the
reagents were scaled up 30-fold using 50nM siRNA. ABCG2 mRNA
levels were analysed 48h after transfection by real-time RT–PCR
for the initial siRNA screening. RNA levels for the comparison of
12.5 and 50nM were analysed 48h after transfection using the
QuantiGene Reagent System (Panomics, Fremont, CA, USA) and
normalised to cyclophilin B (PPIB) mRNA. The results reflect the
average and s.d. of at least five replicate experiments. ABCG2
protein levels were measured by western blotting as described
above 48h after siRNA transfection. For drug analysis, cells were
grown for 48h before adding various concentrations of mitoxan-
trone for 72h as described above.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed on
MCF-7, MCF7/FLV1000 and five single-step doxorubicin-selected
clones. Briefly, cells (1 10
6) were crosslinked with 1% formalde-
hyde for 10min at 371C, quenched with 0.125 M glycine for 5min at
RT and rinsed in ice-cold PBS containing 5mM sodium butyrate
(Sigma, St Louis, MI, USA). Cells were scraped and re-suspended
in a lysis buffer (Active Motif, Carlsbad, CA, USA) with the
addition of complete protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN, USA). DNA–protein complexes were
sheared using an enzymatic shearing kit (Active Motif) to yield
DNA fragments below 800bp, as determined by agarose gel
electrophoresis. Chromatin immunoprecipitations were carried
out overnight at 41C with 10mg of anti-acetylated H3 (AcH3), 5mg
of anti-histone deacetylase 1 (HDAC1; Upstate Biotechnology,
Charlottesville, VA, USA) and 2mg of anti-RNA polymerase II (Pol II;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primer sets
encompassing approximately 1.6kb of the ABCG2 promoter were
used to map changes in histone acetylation after drug selection.
The amount of immunoprecipitated DNA was assessed by
quantitative PCR, using primers spanning the proximal ( 293 to
–139nt) and distal ( 1527 to –1268nt) promoter region of
ABCG2, and compared to the amount of input DNA prior to
immunoprecipitation. The numbering of the nucleotides was
assigned relative to the transcriptional start site designated
in GenBank sequence AF151530. Amplification of immunopreci-
pitated DNA was achieved using previously described methods
(To et al, 2006).
RESULTS
Single-step doxorubicin selection results in ABCG2
overexpression
The gene expression profiles of select ABC transporters (ABCB1,
ABCC1, ABCC2, ABCC4 and ABCG2) linked to MDR (Perez-
Tomas, 2006) were assayed using qRT–PCR in MCF-7 cells
subjected to drug selection. These transporters have been
associated with the MDR phenotype in various cell lines (Perez-Tomas,
2006). Briefly, ten thousand cells (in a 100 20mm dish)
were treated for 10 days with low-dose doxorubicin. Drug selection
with either 14 or 21nM doxorubicin was performed. These doses
were chosen because they are significantly below the IC50 of
doxorubicin for MCF-7 cells, which is B90nM (Table 1). Following
the 10-day drug selection, single isolated cells were chosen
randomly for expansion. The ABC transporter expression patterns
for six doxorubicin-resistant MCF-7 clones selected with 14nM
doxorubicin and one 21nM doxorubicin-resistant clone are shown
in Figure 1A. We also performed selections at higher concentra-
tions of doxorubicin (70, 140 and 210nM). No MCF-7 cells survived
this selection pressure, suggesting that pre-existing cells exhibiting
high levels of ABC transporters within the MCF-7 parental
population were not present. In contrast to the previously
established multistep-selected line MCF7/ADR (Mehta, 1994),
most of the low-concentration clones did not express ABCB1
(Figure 1A). Only the 14nM doxorubicin-selected MCF-7 clone 13
showed a slight increase in ABCB1 at the mRNA level; yet, no
detectable levels of ABCB1 protein were found in this clone
(Figure 2A). On the contrary, all single-step-selected clones
showed overexpression of ABCG2 (4- to 30-fold) when compared
to their parental MCF-7 cells.
To determine if this pattern of expression of MDR-associated
ABC transporters following below IC50 selection was drug and cell
line independent, we selected MCF-7 cells with a single-step
selection using 300nM etoposide and two additional cancer lines,
IGROV-1 ovarian cancer cells and S-1 colon tumor cells, with 14
and 21nM doxorubicin, respectively (Figure 1B–D). With lower
etoposide concentrations of 50, 100 and 200nM, all MCF-7 parental
cells were able to survive the selection pressure. For IGROV-1 cells,
no parental cells survived the 21nM selection. We also studied five
sublines derived from IGROV-1 cells obtained using 14nm
doxorubicin as well as S-1-resistant clones, obtained at a 21nM
concentration of doxorubicin. In all cases, ABCG2 was the
dominant overexpressed gene; the etoposide-selected MCF-7 cells
and the doxorubicin-selected S-1 increased ABCG2 mRNA levels
43-fold while IGROV-1 cells exhibited a nearly 400-fold increase.
This suggests that ABCG2 overexpression is an early molecular
Table 1 Sensitivity of clones to doxorubicin and mitoxantrone
Parental
MCF-7 14nM clone 1 14nM clone 2 14nM clone 6 14nM clone 11 14nM clone 13 14nM clone 16 21nM clone 1
Doxorubicin
IC50 (nM) 89.7 111.1 118.9 173.7 284.7 264.4 260.7 323.0
s.d. 28.2 27.3 50.8 46.3 56.7 65.6 51.8 63.4
Mitoxantrone
IC50 (nM) 15.6 33.1 15.4 319.1 158.6 220.1 172.4 1407.0
s.d. 6.0 6.1 7.5 114.8 11.4 56.2 40.3 310.2
IC50 values are given in nM and are mean±s.d. The IC50 values were calculated from dose–response curves obtained from at least three independent experiments. Cytotoxicity
assays were performed as described in Materials and Methods.
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smarker of the development of MDR in these three cancer cell types.
Two other ABC transporters ABCC2 and ABCC4 were also
overexpressed in some sublines of MCF-7 cells selected with
doxorubicin, exhibiting a 2- to 24-fold and 3- to 10-fold
overexpression of mRNA when compared to the parental MCF-7
cells, respectively.
To examine if the protein expression of these transporters was
also changed, several immunoblots were performed. Consistent
with the mRNA analysis, neither the parental cell line nor any of
the single-step doxorubicin-resistant MCF-7 clones including
clone 13, which showed a slight increase in ABCB1 mRNA,
expressed ABCB1 protein at detectable levels whereas the MCF7/
ADR cells expressed high levels of ABCB1 (Figure 2A, top panel).
Surprisingly, no ABCC2 protein was detected in any of the MCF-7
sublines, although several clones showed a 2- to 24-fold increase of
mRNA compared to the parental MCF-7 cells (Figure 2A, second
panel). The reason for the lack of correlation is not yet clear.
ABCC4 protein was detected in all clones examined (Figure 2A,
third panel). Five of these doxorubicin-selected MCF-7 clones
showed enhanced levels of ABCG2 protein compared to parental
MCF-7 cells, with two clones, 14nM clone 11 and 21nM clone,
showing very high levels (Figure 2A, bottom panel). This analysis
showed enhanced mRNA and protein levels, which was consistent
with the increase in the function and cell surface expression of
ABCG2 in these MCF-7 single-step clones. Interestingly, over-
expression of ABCG2 was retained in the absence of long-term
selection, as both ABCG2 mRNA and protein levels were found to
be increased in cells grown for 24 weeks in the absence of
doxorubicin following the initial drug treatment (data not shown).
To further support these western blotting results, which showed
that the ABCG2 protein was found in the single-step clones,
confocal microscopy studies were also performed to determine if
the ABCG2 protein in the single-step-selected cells was properly
localised to the plasma membrane. Using the 5D3 antibody, which
detects an extracellular epitope of ABCG2 (Zhou et al, 2001), the
cell surface expression of ABCG2 was detected in non-permeabi-
lised cells. The MCF-7 parental cells did not show binding of 5D3
(Figure 2B, left panel); however, the 21nM clone showed a distinct
pattern of binding of 5D3 (Figure 2B, right panel) in intact cells.
This suggested that ABCG2 predominately localised to the plasma
membrane of these cells, where it can be functional as an efflux
transporter.
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Figure 1 Single-step drug-selected clones overexpress ABCG2 mRNA. (A) Characterisation of selected ABC transporter gene expression levels in several
single-step doxorubicin-resistant MCF-7 clones, described in Materials and Methods. The average fold change compared to parental MCF-7 cells±s.d.
(n¼4) was calculated using delta delta Ct method from real-time RT–PCR data. The colour-coded key for the clones is given in the figure. (B) Single-step
etoposide-resistant MCF-7 clones are described in Materials and Methods. The average fold change compared to parental MCF-7 cells±s.d. (n¼4) was
calculated using delta delta Ct method from real-time RT–PCR data. The colour-coded key for the clones is given in the figure. (C) Doxorubicin-resistant
IGROV-1 clones were established employing a single-step selection with 14nM doxorubicin treatment as described previously. The average fold change
compared to parental IGROV-1 cells±s.d. (n¼4) was calculated using delta delta Ct method from real-time RT–PCR data. The colour-coded key for the
clones is given in the figure. (D) Doxorubicin-resistant S-1 clones were established employing a single-step selection with 21nM doxorubicin. The average
fold change compared to parental S-1 cells±s.d. (n¼4) was calculated using delta delta Ct method from real-time RT–PCR data. The key for the clones is
given in each panel.
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sTo confirm that the single-step clones of etoposide-selected
MCF-7 cells, doxorubicin-selected IGROV-1 and doxorubicin-
selected S-1 cells also showed an overexpression of ABCG2 at the
protein level, western blots were performed on these sublines. The
ABCG2 protein expression of the etoposide-selected MCF-7 clone 7
following normalisation to GAPDH levels was 1.9-fold greater than
parental MCF-7 cells (Figure 2C). In addition, the IGROV-1
parental cells show no detectable expression of ABCG2 while
clones 1–7 and 1–11, the two clones showing the greatest increase
in ABCG2 mRNA expression, showed ABCG2 protein expression
(data not shown).
Overexpression of ABCG2 in vitro can cause a mutation at
position 482 (R482-G or T), which alters the substrate specificity
of this transporter (Honjo et al, 2001; Allen et al, 2002). To
determine if this mutation was also present following low-dose,
single-step selection, ABCG2 was sequenced following PCR with
primers covering the region (aa 438–561) (see the Materials and
Methods section in Supplementary Information). Several clones
and MCF-7/ADR-VP3000 cells were sequenced. Sequence data
showed that only the wild-type ABCG2 was present in all clones
(data not shown), while the MCF-7/ADR-VP3000 cells had the
mutation at position R482-T (data not shown), consistent with
what has been reported previously (Honjo et al, 2001).
To show the functional activity of the single-step doxorubicin-
selected clones, we evaluated drug resistance. We examined the
cytotoxicity of doxorubicin for the parental MCF-7 cells and the
single-step-selected 14nM clones and the 21nM clone. The IC50
value for the parental cells was approximately 90nM, while for the
14nM doxorubicin-selected clones 1 and 2, the IC50 values were
only 1.2-fold higher, indicating no increase in resistance to
doxorubicin (Table 1). In contrast, the remaining 14nM doxor-
ubicin-selected MCF-7 clones demonstrated a 2- to 3.2-fold
increase in resistance to doxorubicin. The 21nM doxorubicin-
selected clone was nearly four-fold more resistant to doxorubicin
and over 90-fold more resistant to mitoxantrone (Table 1). Our
data agree with previous reports that demonstrate more resistance
towards mitoxantrone than doxorubicin in cell lines expressing the
wild-type ABCG2 (Honjo et al, 2001). Thus, these clones show not
only resistance to doxorubicin but also demonstrate MDR.
ABCC4 does not confer resistance to doxorubicin
To determine if the expression of ABCC4 can confer resistance to
either doxorubicin or mitoxantrone, additional studies using
ABCC4-overexpressing HEK293 cells were performed. We pre-
viously demonstrated that only ABCC4 is overexpressed in these
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Figure 2 Single-step drug-selected MCF-7 clones overexpress ABCG2 protein. (A) Western blotting analysis of selected ABC drug transporters in
doxorubicin-selected MCF-7 clones. Lanes 1–8 are the same in all panels and only lane 9 varies in each panel. A total of 100000 cells were loaded per lane
for lanes 1–8. Lane 1, parental MCF-7; lane 2, 14nM clone 1; lane 3, 14nM clone 2; lane 4, 14nM clone 6; lane 5, 14nM clone 11; lane 6, 14nM clone 13; lane
7, 14nM clone 16; and lane 8, 21nM clone. Top panel lane 9, 10000 MCF7/ADR cells (positive control); second panel lane 9, 20000 LLCPK-ABCC2 cells
(positive control); third panel lane 9, 2000 ABCC4-HEK293 cells (positive control); and bottom panel lane 9, 5000 MCF7/FLV1000 cells (positive control).
Immunoblotting with antibodies specific for each transporter (as indicated on the right side of each panel) was carried out as described in Materials and
Methods. (B) Cell surface localisation of ABCG2 in 21nM doxorubicin-selected MCF-7 clone. 5D3 binding in MCF-7 (left panel) and 21nM clone cells (right
panel) is shown. Confocal imaging was performed on permeabilised cells following binding with the ABCG2-specific 5D3 antibody (Zhou et al, 2001) as
described in Materials and Methods. Nuclei were stained with DAPI, blue stain (showing as light grey in print); Alexa-Fluor 488 secondary antibody (green)
(white in print) was used to localise 5D3 binding. (C) Western blotting analysis of ABCG2. A total of 100000 cells were loaded per lane for lanes 1 and 2.
Lane 1, MCF-7; lane 2, 300nM etoposide-selected MCF-7 clone 7. Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control.
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scells (Wu et al, 2005). Cytotoxicity assays with doxorubicin were
performed comparing HEK293 cells to ABCC4-overexpressing
HEK293 cells, and no significant differences were found in the
ABCC4-overexpressing HEK293 compared to the parental HEK293
cells, IC50 values 14.9±1.2 and 10.7±1.0nm, respectively
(Figure 3A). Additional cytotoxicity assays were performed to
determine if ABCC4 can confer resistance to mitoxantrone
(Figure 3B). Similar to the assays with doxorubicin, no significant
differences were found in the ABCC4-overexpressing HEK293
compared to the parental HEK293 cells. This suggests that ABCC4
is not responsible for the observed resistance to doxorubicin or
mitoxantrone in single-step-selected clones.
ABCG2 confers drug resistance to single-step doxorubicin-
selected MCF-7 cells
To further evaluate if ABCG2 was conferring resistance to
doxorubicin in the 21nM MCF-7 clone, we performed cytotoxicity
assays in the presence and absence of fumitremorgin C (FTC)
(Rabindran et al, 2000), a specific inhibitor of ABCG2. With the
addition of 5mM FTC, we were able to reverse the ABCG2-mediated
resistance to doxorubicin (Figure 4A) to levels comparable to those
of the parental MCF-7 cells (Table 1). The addition of FTC resulted
in a 2.1-fold enhancement of the toxicity of doxorubicin on the
21nM doxorubicin-selected MCF-7 cells. This indicates that the
inhibition of ABCG2 results in greater toxicity of doxorubicin in
these cells.
To confirm that ABCG2 was the ABC transporter conferring
resistance to the single-step clones, RNA interference (RNAi)
studies were also performed. Standard characterisation analysis
was conducted to determine the degree of silencing mediated by a
synthetic siRNA corresponding to ABCG2 (siG2-2). Using 50nM
siRNA, ABCG2 mRNA was decreased by nearly 40-fold compared
to a negative siRNA in the 21nM MCF7 clone and ABCG2 protein
expression was almost completely suppressed (Figure 4B). A lower
concentration of siRNA was also examined, and comparable
silencing was also observed at an mRNA level using 12.5nM siRNA
(Figure 4C).
Following validation, cytotoxicity assays were performed on
cells treated with siG2-2 or negative control siRNA. The siG2-2
siRNA induced a shift of the drug response curve to the left,
indicating less resistance to mitoxantrone (Figure 4D). The IC50
value for the siG2-2-treated cells was three-fold less than that for
the negative siRNA-treated cells. Silencing with siG2-2 restored
sensitivity to approximately 80–85% of the parental levels.
Together with the results from the FTC cytotoxicity studies, this
suggests that ABCG2 is critical for the drug resistance in the single-
step 21nM doxorubicin-selected MCF-7 cells.
Histone acetylation is modified at the ABCG2 locus in the
single-step doxorubicin-selected clones
To determine whether expression of ABCG2 was associated with
epigenetic changes such as histone acetylation, we performed ChIP
assays to measure the interaction of the protein with a specific
DNA sequence in vivo (Kuo and Allis, 1999). We used ChIP to
investigate the level of AcH3, HDAC1 and RNA Pol II associated
with different segments of the ABCG2 gene. Compared with the
parental MCF-7 cells, the enrichment of H3 acetylation to the
proximal ABCG2 promoter was enhanced more than 10-fold but
there was less association of HDAC1 (approximately 50%
decrease) in the selected clones and in a well-characterised
resistant subline MCF7/FLV1000 (Robey et al, 2001) (Figure 5A
and B). The loss of HDAC1 and the stronger binding of Pol II to
the proximal promoter correlated well with the enhanced
transcription of ABCG2 in these cells. As a control, the weak
association of Pol II, AcH3 and HDAC1 to the distal ABCG2
promoter remained similar in the parental, resistant MCF7/
FLV1000 and the doxorubicin-selected clones. The GAPDH
promoter was employed as an additional control. Compared with
the parental MCF-7 cells, the drug-selected clones expressed a
similar level of GAPDH, as determined by RT–PCR (data not
shown). To determine whether drug selection-related histone H3
hyperacetylation was specific to the ABCG2 promoter, we assessed
the association of Pol II, AcH3 and HDAC1 with the housekeeping
gene GAPDH promoter. Accordingly, ChIP analysis did not reveal
any appreciable difference in the binding of Pol II, AcH3 and
HDAC1 to the GAPDH promoter between the parental and the
drug-selected sublines (Figure 5A and B). This correlated with the
strong binding of Pol II and AcH3 and the weak association of
HDAC1 to the proximal promoter of GAPDH that did not change
from the parental to the selected clones. These results demonstrate
that increased histone H3 acetylation in the proximal ABCG2
promoter in response to doxorubicin selection was gene-specific.
In contrast, immunoblot analysis of whole-cell lysates demon-
strated that drug selection did not globally change the level of
histone H3 acetylation in the doxorubicin-selected clones or in
MCF7/FLV1000 (Figure 5C). The lack of global changes in histone
acetylation supports the notion that regional accumulation of
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Figure 3 ABCC4 does not confer resistance to doxorubicin or
mitoxantrone. (A) Cytotoxicity assays for ABCC4-overexpressing
HEK293 (’) and parental HEK293 (&) cells with doxorubicin. Dose–
response curves were derived from three independent experiments using
the CCK-8 assay. (B) Cytotoxicity assays for ABCC4-overexpressing
HEK293 (n) and parental HEK293 (K) cells with mitoxantrone. CCK-8
reagent was used for cytotoxicity assays as described in Materials and
methods. Dose–response curves were derived from three independent
experiments. In both (A) and (B), error bars indicate s.d. (n¼3).
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sacetylated histone (revealed by the ChIP assay) in the ABCG2
proximal promoter is specific to the ABCG2 promoter and
specifically due to drug selection. Doxorubicin selection did not
alter the levels of global core histone acetylation, which are
undetectable. As a control, HDAC inhibition by depsipeptide
results in hyperacetylation of H3 in the whole-cell lysate, again
supporting the specificity of the reduced HDAC1 bound to the
ABCG2 promoter (Figure 5C). The expression of HDAC1 was not
significantly different among the various sublines.
DISCUSSION
Doxorubicin is a chemotherapeutic agent principally used for the
treatment of solid tumours, especially breast cancer and lymphoma
(Minotti et al, 2004). Although doxorubicin can work through
various mechanisms, it is still not immune to the MDR phenotype
and, consequently, the development of resistance to doxorubicin
has been well documented in a broad range of cell lines (Shen et al,
1986; Barrand et al, 1994; Mehta, 1994). To more closely examine
the regulation of ABC transporter expression at concentrations
similar to those in vivo, we established several single-step
doxorubicin-selected clones with three different cancer cell lines
and found that these clones did not express ABCB1 (Figure 1).
Although ABCC2 and ABCC4 were overexpressed at the mRNA
level, ABCG2 was the only transporter responsible for resistance in
these clones (Figures 3 and 4). In addition, a podophyllotoxin
derivative, etoposide (Hande, 1998), was also able to solicit the
same response in MCF-7 cells after single-step selection (Figures
1B and 2C). Moreover, the selection of IGROV-1 and S-1 cancer
cells with 14 or 21nM doxorubicin also resulted in the over-
expression of ABCG2 (Figure 1C and D). We cannot completely
rule out the possibility that a pre-existing cell with high expression
of ABCG2 was present in the parental population; nevertheless, we
found an overexpression of ABCG2 following low-dose selection in
three independent cell lines originating from different tissues using
two different drugs. In addition, the lack of enrichment in the
putative mammary cancer stem cell surface phenotype, CD44þ/
CD24  (Al-Hajj et al, 2003) (Supplementary Figure 1), in the
single-step doxorubicin-selected MCF-7 clones further supports
the theory of adaptation over selection with these studies.
Doxorubicin and etoposide are structurally different but they
are both topoisomerase II inhibitors and this may explain the
similarities in the response of cells to selection with these agents;
however, further studies will be required to establish this. Others
have also investigated the effects of single-step doxorubicin
selection on the human sarcoma cell line MES-SA and have
reported an increase in ABCB1 expression (Chen et al, 1994;
Beketic-Oreskovic et al, 1995); yet previous studies were
performed before the identification of ABCG2 as a major ABC
transporter in the area of MDR. In addition, the authors used
40nM doxorubicin for 14 days, nearly two-fold higher than the
concentration we employed. We have examined the endogenous
levels of ABCG2 in the MES-SA parental cells, and it is not
detectable by real-time PCR (data not shown). It is possible that in
this cell type, ABCB1 is responsible for resistance; however, as
these original studies did not report other ABC transporters, we
cannot address this question. We will determine in the future if a
single-step drug regimen results in the same ABC transporters
being overexpressed in vivo.
ABCG2 is a half-transporter that appears to have a protective
role in a variety of stem cells to maintain progenitor cells in an
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Figure 4 ABCG2 confers resistance to 21nM single-step doxorubicin-selected clone. (A) Cytotoxicity assays using doxorubicin to evaluate the effect of
inhibiting ABCG2 in the 21nM single-step clone with 5mM FTC. Dose–response curves were derived from six independent experiments using the CCK-8
assay for 21nM cells with 5mM FTC (n) and without 5mM FTC (’). The mean values from six independent experiments are shown with error bars as s.e.m.
(B) Western blotting analysis of ABCG2 protein using BXP-21 antibody following no treatment (lane 1), 50nM negative siRNA treatment (lane 2) and 50nM
G2-2 siRNA treatment (lane 3). (C) Examination of two concentrations of siG2-2 siRNA on silencing of ABCG2. Levels of ABCG2 following siRNA treatment
were analysed using the QuantiGene Reagent System (Panomics). Levels were normalised to cyclophilin B (PPIB) mRNA and results reflect the average and
s.d. (n¼5). (D) Cytotoxicity assays using mitoxantrone to evaluate the effect of silencing ABCG2 in the 21nM single-step clone. Dose–response curves were
derived from six independent experiments using the CCK-8 assay for 21nM cells with 12.5nM siG2-2 siRNA (&) and 21nM cells with 12.5nM siNeg (m).
The mean values from six independent experiments are shown with error bars as s.e.m.
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sundifferentiated state (Zhou et al, 2001) and is often referred to as
a stem cell marker. This ABC transporter is also highly expressed
in the placenta, liver and small intestine (reviewed by Krishna-
murthy and Schuetz, 2006) where it is influential in the absorption
and distribution of xenobiotics. However, to date, the role of this
transporter in clinical drug resistance has not been evaluated in
any extensive clinical trial (Robey et al, 2007). Interestingly, one
smaller study with 59 primary breast cancer patients reported a
negative correlation between ABCG2 mRNA expression and
response rate and progression-free survival with anthracycline-
based chemotherapy (Burger et al, 2003). Investigators first
determined that stem cells from rhesus monkey bone marrow,
mouse skeletal muscle and murine embryonic stem cells, which
constitute the ‘side population’ of effluxing cells, expressed ABCG2
(Zhou et al, 2001). In addition, the expression of ABCG2 has been
linked to prostate stem cells and mammary gland stem cells
(Clayton et al, 2004; Huss et al, 2005). ABCG2 may serve as the
primary line of defence against the cytotoxic effects of drug in our
single-step-selected clones, as it does in stem cells. However, these
cells were not enriched in the putative mammary cancer stem cell
surface phenotype, CD44þ/CD24  (Al-Hajj et al, 2003) (Supple-
mentary Figure 1), suggesting that we have not selected for cancer
stem cells in these studies and that the epigenetic changes that
occurred in the sublines were a result of adaptation as opposed to
selection. Others have also reported adaptation of cells to drug
pressure as the mechanism of drug resistance (Matsumoto et al,
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Figure 5 ABCG2 chromatin in the doxorubicin-selected clones is associated with more RNA Pol II and AcH3 but less HDAC1 than the parental MCF-7
cell line. (A) Chromatin immunoprecipitation assays were performed with parental MCF-7 cells and the doxorubicin-selected clones (Kuo and Allis, 1999). A
drug-resistant subline MCF7/FLV1000 (Robey et al, 2001) was employed as a control. Soluble chromatin used in immunoprecipitations had a typical size of
o0.5kb visualisation by gel electrophoresis. RNA Pol II, AcH3 or HDAC1 associated with the distal and proximal region in the ABCG2 promoter were
analysed by PCR. Lane 1, parental MCF-7; lane 2, 14nM clone 2; lane 3, 14nM clone 6; lane 4, 14nM clone 13; lane 5, 21nM clone; and lane 6, MCF7/
FLV1000. Input: DNA isolated from the lysate before immunoprecipitation. A representative result from three independent experiments is shown.
(B) Quantitative analyses of the occupancy of Pol II, AcH3 or HDAC1 to the ABCG2 promoter (proximal and distal regions) in the cells. The results are
expressed as the percentage of immunoprecipitate (IP) over total input DNA. Error bars show the s.d. of three independent experiments. Lanes 1–6 are
the same as above. (C) Western blot analysis of AcH3 and HDAC1. Whole-cell lysates were prepared from the parental MCF-7 cells and the various single-
step doxorubicin-selected MCF-7 clones for AcH3 (17kDa) and HDAC1 (65kDa) detection, respectively. Samples 1–6 are as follows: 1, parental MCF-7; 2,
14nM clone 2; 3, 14nM clone 6; 4, 14nM clone 13; 5, 21nM clone; and 6, MCF7/FLV1000. As a control, HDAC inhibition by depsipeptide results in
hyperacetylation of H3 in the whole-cell lysate (control lane). Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control for each sample.
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s1997). Microarray analysis of these single-step doxorubicin-
selected MCF-7 clones shows that gene expression changes were
found primarily in molecular and cellular functions related to cell
death, cancer and inflammatory disease (data not shown). This
suggests that adaptation to cell stressors such as these may be
responsible for turning on the drug resistance genes.
The inhibition of ABCG2 by FTC and the silencing of ABCG2
through siRNA-mediated RNAi showed reversal of drug resistance,
confirming that ABCG2 overexpression is responsible for drug
resistance (Figure 4). Although ABCC4 expression was seen in
these clones, mitoxantrone was not a substrate for ABCC4
(Figure 3B), and ABCC4 did not confer resistance to doxorubicin
(Figure 3A). Thus, this transporter is unlikely to be associated
with drug resistance in the single-step-selected clones. Using
PAGen@UIC (www.uic.edu/pharmacy/depts/pmpcpd/pagen/), we
found that there are 11 predicted transcription factors that have
binding sites on the promoters of both ABCG2 and ABCC4
(Kamalakaran et al, 2005). Thus, it is possible that the coordinate
overexpression of both transporters may be due to an effect of
common transcription factors. Further work is necessary to
unravel the mechanism of this coordinate overexpression.
In this report, we have shown a reproducible pattern of histone
acetylation at the ABCG2 gene that was modified in the clones
selected by doxorubicin treatment and in resistant cells (MCF7/
FLV1000) overexpressing ABCG2 (Figure 5). Presumably, HDAC1,
specifically bound to the ABCG2 proximal promoter close to the
transcriptional initiation site in the parental MCF-7 cells,
suppressed histone acetylation at the ABCG2 gene. Therefore, as
compared to the parental MCF-7 cells, the weaker association of
HDAC1 with the proximal ABCG2 promoter in the selected clones
and in MCF7/FLV1000 facilitated histone hyperacetylation and
subsequently transcriptional upregulation of ABCG2 (Figure 5).
Upregulation of ABCB1, a classical MDR gene, by chemothera-
peutic drugs has also been shown to be associated with changes in
the spatial and temporal patterns of histone H3 acetylation (Baker
et al, 2005). Further interesting evidence was gleaned from our
microarray mRNA expression studies coupled with pathway
analysis, indicating that the oestrogen receptor may regulate the
expression of ABCG2 (data not shown). This hypothesis is
supported by recent work that showed the presence of an
oestrogen response element in the ABCG2 gene (Ee et al, 2004).
Additional studies are necessary to elucidate the role of the
oestrogen receptor in ABCG2 overexpression. To our knowledge,
this is the first report of ABCG2 overexpression following single-
step selection with low concentrations of doxorubicin in breast,
ovarian and colon cancer cells. Further work will elucidate the
triggers that are required to alter expression of these transporters.
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